BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Pilato V, Aiezza N, Viaggi V, Antonelli A, Principe L, Giani T, Luzzaro F, Rossolini GM. KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam. Antimicrob Agents Chemother 2020;65:e01429-20. [PMID: 33106265 DOI: 10.1128/AAC.01429-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Piccirilli A, Cherubini S, Celenza G, Rossolini GM, Brisdelli F, Segatore B, Principe L, Luzzaro F, Andriani L, Amicosante G, Perilli M. A Two Amino Acid Duplication, L167E168, in the Ω-Loop Drastically Decreases Carbapenemase Activity of KPC-53, a Natural Class A β-Lactamase. Antimicrob Agents Chemother 2022;:e0240221. [PMID: 35647648 DOI: 10.1128/aac.02402-21] [Reference Citation Analysis]
2 Jousset AB, Oueslati S, Emeraud C, Bonnin RA, Dortet L, Iorga BI, Naas T. KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate. Antimicrob Agents Chemother 2021;65:e0116021. [PMID: 34606331 DOI: 10.1128/AAC.01160-21] [Reference Citation Analysis]
3 Valzano F, Boncompagni SR, Micieli M, Di Maggio T, Di Pilato V, Colombini L, Santoro F, Pozzi G, Rossolini GM, Pallecchi L. Activity of N-Acetylcysteine Alone and in Combination with Colistin against Pseudomonas aeruginosa Biofilms and Transcriptomic Response to N-Acetylcysteine Exposure. Microbiol Spectr 2022;:e0100622. [PMID: 35735984 DOI: 10.1128/spectrum.01006-22] [Reference Citation Analysis]
4 Sadek M, Poirel L, Dominguez Pino M, D'Emidio F, Pomponio S, Nordmann P. Evaluation of SuperCAZ/AVI® Medium for Screening Ceftazidime-avibactam Resistant Gram-negative Isolates. Diagn Microbiol Infect Dis 2021;101:115475. [PMID: 34419742 DOI: 10.1016/j.diagmicrobio.2021.115475] [Reference Citation Analysis]
5 Gaibani P, Amadesi S, Lazzarotto T, Ambretti S. Genome characterization of a Klebsiella pneumoniae co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically ill patient. J Glob Antimicrob Resist 2022;30:262-4. [PMID: 35777673 DOI: 10.1016/j.jgar.2022.06.021] [Reference Citation Analysis]
6 Liao Q, Deng J, Feng Y, Zhang W, Wu S, Liu Y, Che H, Xie Y. Emergence of Ceftazidime-Avibactam Resistance Due to A Novel blaKPC-2 Mutation during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Journal of Infection and Public Health 2022. [DOI: 10.1016/j.jiph.2022.04.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Gaibani P, Bussini L, Amadesi S, Bartoletti M, Bovo F, Lazzarotto T, Viale P, Ambretti S. Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient. Microorganisms 2022;10:778. [DOI: 10.3390/microorganisms10040778] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Sun L, Li H, Wang Q, Liu Y, Cao B. Increased gene expression and copy number of mutated blaKPC lead to high-level ceftazidime/avibactam resistance in Klebsiella pneumoniae. BMC Microbiol 2021;21:230. [PMID: 34412588 DOI: 10.1186/s12866-021-02293-0] [Reference Citation Analysis]
9 Poirel L, Sadek M, Kusaksizoglu A, Nordmann P. Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants. Eur J Clin Microbiol Infect Dis 2022. [PMID: 35088164 DOI: 10.1007/s10096-021-04397-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]